# SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

> **NCT03050229** · PHASE4 · COMPLETED · sponsor: **Jichi Medical University** · enrollment: 174 (actual)

## Conditions studied

- Nocturnal Hypertension
- T2DM (Type 2 Diabetes Mellitus)

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03050229
- **Lead sponsor:** Jichi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2017-10
- **Final completion:** 2018-03
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2018-03-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03050229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03050229, "SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03050229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*